These findings identify TRPV1 activation as a central mediator of SARS-CoV-2-induced neurodegeneration in the olfactory epithelium and suggest that TRPV1 antagonism offers a promising therapeutic avenue for treating COVID-19-related anosmia. The gene discussed is TRPV1; the disease is Kallmann syndrome.